PubMed Health⌕ Search

PubMed · 16851682

Self-assembling bipyridinium multilayers.

Abstract

The identification of strategies to assemble nanostructured films with engineered properties on solid supports can lead to the development of innovative functional materials. In particular, the self-assembly of electroactive multilayers from simple molecular building blocks on metallic electrodes can offer the opportunity to regulate the exchange of electrons between the underlying substrate and solution species. In this context, we designed an experimental protocol to prepare electroactive films from bipyridinium bisthiols. Specifically, we found that a compound incorporating two bipyridinium dications at its core and terminal thiol groups self-assembles into remarkably stable multilayers on polycrystalline gold. The surface coverage of the resulting films can be regulated by adjusting the exposure time of the gold substrate to the bipyridinium solution. Control experiments with appropriate model compounds demonstrate that both bipyridinium dications as well as both thiol groups must be present in the molecular skeleton to encourage multilayer growth. The resulting films transport electrons efficiently from the electrode surface to the film/solution interface. Indeed, they mediate the reduction of Ru(NH(3))(6)(3+) in the electrolyte solution but prevent the back oxidation of the resulting Ru(NH(3))(6)(2+). Furthermore, these polycationic bipyridinium films capture electrostatically Fe(CN)(6)(4-) tetraanions, which can also be exploited to transport electrons across the interfacial assembly. In fact, electrons can travel through the bipyridnium(2+/1+) couples to redox probes in solution and then back to the electrode through the Fe(CN)(6)(4/3-) couples. Thus, our original approach to self-assembling multilayers can produce stable electroactive films with unique electron transport properties, which can be regulated with a careful choice of the anionic components.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Robert J Alvarado, Jhindan Mukherjee, Eden J Pacsial, Daniel Alexander, Françisco M Raymo. 2005-04-07. Self-assembling bipyridinium multilayers.. https://doi.org/10.1021/jp044797i

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗